PMID- 12778005
OWN - NLM
STAT- MEDLINE
DCOM- 20040423
LR  - 20191210
IS  - 1541-2016 (Print)
IS  - 1533-4058 (Linking)
VI  - 11
IP  - 2
DP  - 2003 Jun
TI  - HER-2 analysis in tissue microarrays of archival human breast cancer: comparison 
      of immunohistochemistry and fluorescence in situ hybridization.
PG  - 177-82
AB  - HER-2 gene alterations have been shown to have prognostic and predictive value 
      for the treatment of breast cancer with therapeutic agents. As a result, the 
      accurate evaluation of HER-2 status is crucial. HER-2 status is assessed at the 
      protein level by immunohistochemistry and at the DNA level by fluorescence in 
      situ hybridization (FISH). Although the best approach is to combine 
      immunohistochemistry and FISH assays, doing so is not practical or cost-effective 
      for routine histopathologic laboratories. The recent development of tissue 
      microarray technology has allowed large-scale studies using formalin-fixed, 
      paraffin-embedded material. We used this technique to assess HER-2 status in a 
      cohort of 54 invasive breast cancer cases by immunohistochemistry and FISH assays 
      to determine whether the results obtained were representative of the protein and 
      gene expression patterns of the original whole tissue section. Concordance for 
      HER-2 immunohistochemistry between the tissue microarray and full sections was 
      93%. Concordance for HER-2 FISH between the tissue microarray and full sections 
      was 91%. Concordance between HER-2 FISH and HER-2 immunohistochemistry on the 
      tissue microarray was 98%. We conclude that tissue microarrays provide highly 
      comparable results in the assessment of HER-2 protein levels and allow 
      large-scale analysis of the HER-2 gene by FISH.
FAU - O'Grady, Anthony
AU  - O'Grady A
AD  - Department of Pathology, Beaumont Hospital, Dublin, Ireland. togrady@rci.ie
FAU - Flahavan, Claire M
AU  - Flahavan CM
FAU - Kay, Elaine W
AU  - Kay EW
FAU - Barrett, Helen L
AU  - Barrett HL
FAU - Leader, Mary B
AU  - Leader MB
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/diagnosis/*pathology
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Reproducibility of Results
MH  - Staining and Labeling
EDAT- 2003/06/05 05:00
MHDA- 2004/04/24 05:00
CRDT- 2003/06/05 05:00
PHST- 2003/06/05 05:00 [pubmed]
PHST- 2004/04/24 05:00 [medline]
PHST- 2003/06/05 05:00 [entrez]
AID - 10.1097/00129039-200306000-00016 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2003 Jun;11(2):177-82. doi: 
      10.1097/00129039-200306000-00016.